Stocks · Financials · Blank Checks

Drugs Made In America Acquisition Corp.

DMAA Clue Score59
United States Fiscal year ends December CIK 0002028614
$10.85 +0.00% Close, 9 Oct 2026
Price $10.85 +5.54% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 25 Feb 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2025Operating income−2.8Net income5.9
FY2025
Operating income −2.8
Net income 5.9
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2025Operating cash flow−0.5
FY2025
Operating cash flow −0.5

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2025Cash0.0Shareholders’ equity−7.3
FY2025
Cash 0.0
Shareholders’ equity −7.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2025 31 Dec 2025
Revenue and profit
2.8
−2.8
Growth
5.9
Growth

Five years in brief

Worked out from the figures above, not from a press release
  • Profitable in every one of the 1 years on file.